PURPOSE: PIK3CA mutation appears to predict a lack of response to anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic colorectal cancer (mCRC). However, the predictive value of PIK3CA mutations for survival remains inconclusive. Here, we pooled the data from published studies to estimate the association between PIK3CA mutation and survival outcomes in mCRC patients treated with anti-EGFR mAbs. METHODS: Studies investigating the association of PIK3CA mutations with clinical survival outcomes of mCRC patients treated with anti-EGFR mAbs were systematically identified. The overall hazard ratio (HR) was estimated by using fixed effect model or random effect model according to heterogeneity between trails. RESULTS: Eight studies that reported survival outcome in 839 mCRC patients were included. In unselected patients, we found that PIK3CA mutations were significantly associated with poorer PFS [8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001] and OS (5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015). With increased predictive power in KRAS wild-type patients (3 studies; 275 patients), the overall HR for PFS was 2.44 (95 % CI 1.33-4.48; P = 0.004) and was statistically significant. We also observed a worse OS in KRAS wild-type patients with PIK3CA mutations (2 studies; 163 patients; HR = 1.37; 95 % CI 0.80-2.35; P = 0.258), although the result was not statistically significant due to small sample size. CONCLUSIONS: PIK3CA mutation is a promising predictive biomarker for poor survival in mCRC patients treated with anti-EGFR mAbs, particularly in KRAS wild-type patients.
PURPOSE:PIK3CA mutation appears to predict a lack of response to anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic colorectal cancer (mCRC). However, the predictive value of PIK3CA mutations for survival remains inconclusive. Here, we pooled the data from published studies to estimate the association between PIK3CA mutation and survival outcomes in mCRC patients treated with anti-EGFR mAbs. METHODS: Studies investigating the association of PIK3CA mutations with clinical survival outcomes of mCRC patients treated with anti-EGFR mAbs were systematically identified. The overall hazard ratio (HR) was estimated by using fixed effect model or random effect model according to heterogeneity between trails. RESULTS: Eight studies that reported survival outcome in 839 mCRC patients were included. In unselected patients, we found that PIK3CA mutations were significantly associated with poorer PFS [8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001] and OS (5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015). With increased predictive power in KRAS wild-type patients (3 studies; 275 patients), the overall HR for PFS was 2.44 (95 % CI 1.33-4.48; P = 0.004) and was statistically significant. We also observed a worse OS in KRAS wild-type patients with PIK3CA mutations (2 studies; 163 patients; HR = 1.37; 95 % CI 0.80-2.35; P = 0.258), although the result was not statistically significant due to small sample size. CONCLUSIONS:PIK3CA mutation is a promising predictive biomarker for poor survival in mCRC patients treated with anti-EGFR mAbs, particularly in KRAS wild-type patients.
Authors: Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele Journal: Oncologist Date: 2007-01
Authors: F Perrone; A Lampis; M Orsenigo; M Di Bartolomeo; A Gevorgyan; M Losa; M Frattini; C Riva; S Andreola; E Bajetta; L Bertario; E Leo; M A Pierotti; S Pilotti Journal: Ann Oncol Date: 2008-07-31 Impact factor: 32.976
Authors: Youji He; Laura J Van't Veer; Izabela Mikolajewska-Hanclich; Marie-Louise F van Velthuysen; Eliane C M Zeestraten; Iris D Nagtegaal; Cornelis J H van de Velde; Corrie A M Marijnen Journal: Clin Cancer Res Date: 2009-11-10 Impact factor: 12.531
Authors: Hans Prenen; Jef De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar Journal: Clin Cancer Res Date: 2009-04-14 Impact factor: 12.531
Authors: F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg Journal: Br J Cancer Date: 2007-03-20 Impact factor: 7.640
Authors: Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak Journal: J Mol Diagn Date: 2017-02-06 Impact factor: 5.568
Authors: Andrew Moriarity; Jacintha O'Sullivan; John Kennedy; Brian Mehigan; Paul McCormick Journal: Ther Adv Med Oncol Date: 2016-05-29 Impact factor: 8.168
Authors: Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak Journal: Am J Clin Pathol Date: 2017-02-03 Impact factor: 2.493
Authors: Grigoriy A Yanus; Anna V Belyaeva; Alexandr O Ivantsov; Ekatherina Sh Kuligina; Evgeny N Suspitsin; Natalia V Mitiushkina; Svetlana N Aleksakhina; Aglaya G Iyevleva; Olga A Zaitseva; Olga S Yatsuk; Tatiana V Gorodnova; Tatiana N Strelkova; Sofia A Efremova; Alla Yu Lepenchuk; Altn N Ochir-Garyaev; Moisey B Paneyah; Dmitriy E Matsko; Alexandr V Togo; Evgeny N Imyanitov Journal: Med Oncol Date: 2013-08-14 Impact factor: 3.064
Authors: Qingsong Zhu; Evgeny Izumchenko; Alexander M Aliper; Evgeny Makarev; Keren Paz; Anton A Buzdin; Alex A Zhavoronkov; David Sidransky Journal: Hum Genome Var Date: 2015-04-02